Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Ovid Therapeutics (OVID) Accumulated Depreciation & Amortization (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Accumulated Depreciation & Amortization readings, the most recent being $35000.0 for Q1 2026.

  • Quarterly Accumulated Depreciation & Amortization fell 75.18% to $35000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $35000.0 through Mar 2026, down 75.18% year-over-year, with the annual reading at $273000.0 for FY2025, 55.46% down from the prior year.
  • Accumulated Depreciation & Amortization hit $35000.0 in Q1 2026 for Ovid Therapeutics, down from $273000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $613000.0 in Q4 2024 and bottomed at $35000.0 in Q1 2026.
  • Average Accumulated Depreciation & Amortization over 5 years is $290584.8, with a median of $273000.0 recorded in 2025.
  • The largest annual shift saw Accumulated Depreciation & Amortization soared 116.17% in 2022 before it crashed 75.18% in 2026.
  • Ovid Therapeutics' Accumulated Depreciation & Amortization stood at $512505.0 in 2022, then rose by 10.83% to $568000.0 in 2023, then grew by 7.92% to $613000.0 in 2024, then crashed by 55.46% to $273000.0 in 2025, then tumbled by 87.18% to $35000.0 in 2026.
  • Per Business Quant, the three most recent readings for OVID's Accumulated Depreciation & Amortization are $35000.0 (Q1 2026), $273000.0 (Q4 2025), and $256000.0 (Q3 2025).